Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

Diabetes numbers on the rise: Experts worried

According a new international study more than 350 million in the world now have diabetes. The analysis, published online by the Lancet on Saturday, adds several tens of millions to the previous estimate of the number of diabetics and indicates that the disease has become a major global health problem.

27 Jun 2011

New and effective diabetes drug seeking approval

A new drug for diabetes from Bristol-Myers Squibb Co. and AstraZeneca PLC was effective in lowering blood sugar. The pharmaceutical drug makers are looking for approval for the drug, dapagliflozin, as the first in new class of pills designed to lower blood sugar by increasing the amount of glucose excreted in the urine.

27 Jun 2011

Study finds increase in life expectancy for people with type 1 diabetes

The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Medtronic’s sensor-augmented pump therapy improves outcomes for patients with diabetes

Research presented at the American Diabetes Association's 71st Scientific Sessions (ADA) this week adds to the clinical evidence for Medtronic's sensor-augmented insulin pump therapy for improved glucose control for people with type 1 diabetes.

From Medtronic 27 Jun 2011

Mayo Clinic to create artificial pancreas for treating type 1 diabetes

The 25.8 million Americans who have diabetes may soon be free of finger pricks and daily insulin dosing. Mayo Clinic endocrinologists Yogish Kudva, M.B.B.S., and Ananda Basu, M.B.B.S., M.D., are developing an artificial pancreas that will deliver insulin automatically and with an individualized precision never before possible.

27 Jun 2011

Diabetic patients can benefit from basal insulin analogs

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes.

27 Jun 2011

Diabetes more prevalent in every part of the world

A major international study collating and analyzing worldwide data on diabetes since 1980 has found that the number of adults with the disease reached 347 million in 2008, more than double the number in 1980. The research, published today in The Lancet, reveals that the prevalence of diabetes has risen or at best remained unchanged in virtually every part of the world over the last three decades.

27 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

PNP Pharmaceuticals contracted as exclusive global manufacturer of Fero Industries' Sucanon

Fero Industries, Inc. is pleased to announce that it has contracted PNP Pharmaceuticals Inc. as the exclusive global manufacturer of Sucanon®, an oral treatment for type-2 diabetes.

23 Jun 2011

Insights into type I diabetes

A new signal pathway that renders the insulin-releasing beta cell more sensitive to high levels of blood glucose has been discovered by researchers at the Swedish medical university Karolinska Institutet. A second new study reveals a possible way to delay the disease by inhibiting a lipoprotein.

23 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

Atrium to focus on metabolic syndrome, nutrition research

Atrium Innovations Inc., a recognized leading developer, manufacturer and marketer of professionally endorsed, science-based dietary supplements for the health and nutrition industry, today announced a multi-year commitment to nutrition research and to a comprehensive program focusing on metabolic syndrome.

21 Jun 2011

JDRF launches clinical trials network for treatment of type 1 diabetes

Juvenile Diabetes Research Foundation (JDRF) Canada has announced the official launch of its large-scale effort to support clinical trials evaluating new treatments and technologies for type 1 diabetes in Canada.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Obese, overweight and still healthy

It's become an axiom of health that overweight and obese people are not as healthy as their normal weight counterparts. In fact, obesity has been targeted as one of the country's most serious public health problems, with predictions of widespread heart disease, diabetes and cancer among the growing number of Americans who are overweight.

17 Jun 2011

Roundup: Few states raise taxes to ease budgets; Ala. Gov. signs abortion law; Texas House advances bill to turn Medicaid, Medicare into block grants

As 2011 began, the budget situation in state capitals looked more dire than just about anybody could remember. ... With Medicaid, the states had their hands tied. The new federal health care law prohibits states from cutting eligibility or making it harder for people to apply for coverage. So states had to find other ways to control costs. Idaho reduced the amount paid to hospitals and doctors to treat Medicaid patients, an idea that some 30 governors proposed this year.

17 Jun 2011

Overactive mTOR can result in serious disruption of kidney filter in diabetes patients

Diabetes mellitus is one of the most common secondary diseases in modern society. And because it is on the rise, it is also one of the greatest challenges facing medicine today. Diabetes patients do not die as a direct result of the increase in blood sugar, but from the long-term complications of their disease, in which the increase in blood sugar causes damage to blood vessels and organs.

15 Jun 2011